Health-Related Quality-of-Life (HRQoL) in Patients (pts) with Advanced Neuroendocrine Tumors (NET) Treated with Everolimus (EVE): Results from an Open-label, Phase IIIb, Multicenter, Expanded Access Program (EAP)

#903

Introduction: NET is associated with a considerable HRQoL burden.

Aim(s): To assess the effect of EVE treatment on pt-reported outcomes with validated instruments.

Materials and methods: Pts with advanced NET (N=246), WHO PS 0-2, treated with EVE (10 mg/d) were included in EAP until disease progression, unacceptable toxicity, discontinuation, death, until commercial availability of EVE or May 2012, whichever came first. HRQoL was assessed with EORTC QLQ-C30, EORTC QLQ-GINET21 and EQ-5D instruments at baseline, for three 28-day cycles and then at every three cycles (84-day) until end of treatment (EOT). For QLQ-C30 and QLQ-GINET21, a change of >10 points from baseline to EOT was considered clinically significant.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Pavel M, Unger N, Borbath I, Ricci S, Hwang T,

Keywords: everolimus, QoL, NET,